CytoDyn collaborates with amfAR to accelerate HIV cure research

▴ CytoDyn collaborates with amfAR to accelerate HIV cure research
The amfAR Foundation for AIDS Research, to test the ability of Vyrologix (leronlimab) to mediate a functional HIV cure

CytoDyn Inc., a late-stage biotechnology company developing Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it signed an agreement with amfAR, The Foundation for AIDS Research, to test the ability of Vyrologix (leronlimab) to mediate a functional HIV cure. The international organization, amfAR, plays a vital role in AIDS research by identifying critical gaps in the knowledge of HIV and AIDS and supporting groundbreaking studies.

In 2007, Timothy Brown, also known as the “Berlin patient,” became the first documented person cured of HIV following a stem cell transplant from a CCR5-deficient donor. Subsequent attempts to cure HIV via stem cell transplant from donors expressing CCR5 failed, indicating the critical role of CCR5 deficiency in HIV cure. Last year, Adam Castillejo, formerly the “London patient,” became the second documented case of HIV cure after a stem cell transplant from a CCR5-deficient donor.

While it is now recognized that CCR5 is central to these two documented cases of HIV cure, natural CCR5-deficient individuals are rare and finding such donors is extremely difficult. Recently, Vyrologix (leronlimab) successfully protected macaques from retroviral infection, mirroring the protection from HIV seen in CCR5 deficient individuals. CytoDyn’s partnership with amfAR will advance clinical studies to incorporate Vyrologix to mimic a CCR5-deficient stem cell donor and attempt to functionally cure an HIV+ person receiving a stem cell transplant from a donor expressing CCR5.

“Using leronlimab to pharmacologically copy a CCR5-deficient donor for HIV cure is an exciting next step in our journey towards a cure for the 38 million people living with HIV,” stated Kevin Robert Frost, Chief Executive Officer at amfAR. “While a stem cell transplant is unlikely to be rolled out as an HIV cure, demonstrating that leronlimab can functionally phenocopy CCR5 deficiency and replicate the London and Berlin patients would be a major advancement.” As part of the agreement, CytoDyn will provide leronlimab and study support, while amfAR will support groundbreaking study sites to incorporate leronlimab in their cure studies.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We are honored to be in partnership with amfAR and the opportunities to accelerate a search for an HIV cure using this scientific premise. Timothy Brown’s cure ignited hope that a cure can happen through bone marrow transplant from the rare individuals with a delta-32 mutation. The success in our animal studies for HIV with Vyrologix (leronlimab) has provided this opportunity. We are very excited to be supporting this project, and to be a part of this groundbreaking endeavor with amfAR.”

Tags : #CytoDynInc #LatestNewsonCytoDynInc24thNov #amfARFoundation #LatestNewsonamfARFoundation24thNov #LatestPharmaNews24thNov #LatestPharmaCollaboration24thNov #LatestResearchonAIDS #LatestResearonAIDS24thNov #BoneMarrowTransplant

About the Author

Team Medicircle

Related Stories

Loading Please wait...


Trending Now

Actor-Director Sathish Kaushik Died of a Heart Attack at the Age of 66March 09, 2023
Soleus Push-Ups: A Laziest Exercise to Lower Blood Sugar LevelsMarch 09, 2023
World Kidney Day 2023: Be Aware of Kidney DiseasesMarch 09, 2023
Sushmita Sen reveals about suffering from a severe heart attack recently and Addison's disease in 2014March 06, 2023
A significant increase in influenza A H3N2 patients that are accompanied by severe coughing and feverMarch 06, 2023
Is AIDS or HIV curable in Ayurveda?March 03, 2023
Artificial Sweetener Erythritol Raises the Possibility of Heart Attack.March 01, 2023
Difference between HIV and AIDS - When to give antiretroviral therapy?March 01, 2023
Zero Discrimination Day: Let's Raise the Voice Against DiscriminationMarch 01, 2023
International Women’s Day 2023 – Embrace EquityFebruary 28, 2023
Brain Tumors - Types, Symptoms and Risk FactorsFebruary 28, 2023
World Rare Disease Day: End Stigma Against Rare Diseases.February 28, 2023
National Science Day 2023 - Global Science for Global WellbeingFebruary 28, 2023
Eating disorders - Types and their complicationsFebruary 27, 2023
The condition that took away the life of Malayalam filmmaker, Joseph ManuFebruary 27, 2023
World NGO Day 2023 - We make a living by what we get, but we make a life by what we giveFebruary 27, 2023
Functions and Problems of SerotoninFebruary 25, 2023
Arthritis management – Tips to manage arthritis effectivelyFebruary 25, 2023
Apple has undertaken a project of no-prick blood sugar monitoring feature for its watch.February 24, 2023
Bird flu – Jharkhand on alert, know its prevention and symptoms in humansFebruary 24, 2023